Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Research To Practice | Oncology Videos · Dr. Neil Love
December 4, 202552m 3s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Matthew Lunning, including the following topics:
- Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00)
- Overview of the CAR T-cell therapy administration process (4:40)
- Opportunities for referral for CAR T-cell therapy (10:05)
- Selection of a CAR T-cell therapy based on patient characteristics (16:09)
- Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23)
- Safety regulations and mitigation strategies for adverse events (30:36)
- Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16)
- Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09)
- Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09)